{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:57:39Z","timestamp":1794272259131,"version":"4.9.0"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":75,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02688-5","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:44:30Z","timestamp":1779284670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Treg-cell death axis in lung cancer: implications for immune evasion and novel therapeutic strategies"],"prefix":"10.1186","volume":"25","author":[{"given":"Wenping","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueming","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Li-Ann","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon-Cher","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinrui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2688_CR1","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1186\/s12885-025-15209-2","volume":"25","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yu F, Qiu F, Fang K. Global burden of respiratory system cancers in 2022 and 2050: incidence and mortality estimates from GLOBOCAN. BMC Cancer. 2025;25:1832.","journal-title":"BMC Cancer"},{"key":"2688_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16:356\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"2688_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","volume":"19","author":"C Li","year":"2020","unstructured":"Li C, Jiang P, Wei S, Xu X, Wang J. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020;19:116.","journal-title":"Mol Cancer"},{"key":"2688_CR4","doi-asserted-by":"crossref","unstructured":"Wang Y, Li J, Nakahata S, Iha H. Complex role of regulatory T cells (Tregs) in the tumor microenvironment: their molecular mechanisms and bidirectional effects on cancer progression. Int J Mol Sci. 2024;25(13):7346.","DOI":"10.3390\/ijms25137346"},{"key":"2688_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s004649901121","volume":"13","author":"CM Schlachta","year":"1999","unstructured":"Schlachta CM, Poulin EC, Mamazza J. Laparoscopic splenectomy for hematologic malignancies. Surg Endosc. 1999;13:865\u20138.","journal-title":"Surg Endosc"},{"key":"2688_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942\u20139.","journal-title":"Nat Med"},{"key":"2688_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10169","volume":"475","author":"A Facciabene","year":"2011","unstructured":"Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475:226\u201330.","journal-title":"Nature"},{"key":"2688_CR8","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1158\/0008-5472.CAN-10-3143","volume":"71","author":"E Righi","year":"2011","unstructured":"Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D, et al. CXCL12\/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 2011;71:5522\u201334.","journal-title":"Cancer Res"},{"key":"2688_CR9","doi-asserted-by":"crossref","unstructured":"Angioni R, Sanchez-Rodriguez R, Viola A, Molon B. TGF-beta in cancer: metabolic driver of the tolerogenic crosstalk in the tumor microenvironment. Cancers (Basel). 2021;13(3):401.","DOI":"10.3390\/cancers13030401"},{"key":"2688_CR10","doi-asserted-by":"publisher","first-page":"702726","DOI":"10.3389\/fimmu.2021.702726","volume":"12","author":"EN Scott","year":"2021","unstructured":"Scott EN, Gocher AM, Workman CJ, Vignali DAA. Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment. Front Immunol. 2021;12:702726.","journal-title":"Front Immunol"},{"key":"2688_CR11","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","volume":"188","author":"Z Liu","year":"2025","unstructured":"Liu Z, Yang Z, Wu J, Zhang W, Sun Y, Zhang C, Bai G, Yang L, Fan H, Chen Y, et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell. 2025;188:3081\u2013e30963019.","journal-title":"Cell"},{"key":"2688_CR12","doi-asserted-by":"publisher","first-page":"1691980","DOI":"10.3389\/fimmu.2025.1691980","volume":"16","author":"X Shi","year":"2025","unstructured":"Shi X, Deng W, Pan Y, Chen Y, Wang Y, Wu J. Overcoming resistance to immune checkpoint inhibitor in non-small cell lung cancer: the promise of combination therapy. Front Immunol. 2025;16:1691980.","journal-title":"Front Immunol"},{"key":"2688_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/JTO.0000000000000364","volume":"10","author":"K Kurose","year":"2015","unstructured":"Kurose K, Ohue Y, Sato E, Yamauchi A, Eikawa S, Isobe M, Nishio Y, Uenaka A, Oka M, Nakayama E. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760). J Thorac Oncol. 2015;10:74\u201383.","journal-title":"J Thorac Oncol"},{"key":"2688_CR14","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jtcvs.2010.11.056","volume":"141","author":"O Wald","year":"2011","unstructured":"Wald O, Izhar U, Amir G, Kirshberg S, Shlomai Z, Zamir G, Peled A, Shapira OM. Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12\/CXCR4 axis: role in non-small cell lung cancer tumor proliferation. J Thorac Cardiovasc Surg. 2011;141:1503\u201312.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2688_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","volume":"21","author":"H Wang","year":"2020","unstructured":"Wang H, Franco F, Tsui YC, Xie X, Trefny MP, Zappasodi R, Mohmood SR, Fernandez-Garcia J, Tsai CH, Schulze I, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat Immunol. 2020;21:298\u2013308.","journal-title":"Nat Immunol"},{"key":"2688_CR16","doi-asserted-by":"publisher","first-page":"109235","DOI":"10.1016\/j.celrep.2021.109235","volume":"35","author":"C Xu","year":"2021","unstructured":"Xu C, Sun S, Johnson T, Qi R, Zhang S, Zhang J, Yang K. The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Rep. 2021;35:109235.","journal-title":"Cell Rep"},{"key":"2688_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.canlet.2019.10.032","volume":"469","author":"R Wang","year":"2020","unstructured":"Wang R, Feng W, Wang H, Wang L, Yang X, Yang F, Zhang Y, Liu X, Zhang D, Ren Q, et al. Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model. Cancer Lett. 2020;469:151\u201361.","journal-title":"Cancer Lett"},{"key":"2688_CR18","doi-asserted-by":"publisher","first-page":"1703211","DOI":"10.3389\/fimmu.2025.1703211","volume":"16","author":"P Basurto-Olvera","year":"2025","unstructured":"Basurto-Olvera P, Serrano H, Maldonado-Bernal C. Regulatory T cells in cancer: from immunosuppression to therapeutic targeting. Front Immunol. 2025;16:1703211.","journal-title":"Front Immunol"},{"key":"2688_CR19","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41419-025-08204-9","volume":"16","author":"J Liu","year":"2025","unstructured":"Liu J, Dong R, Yuan B, Xie Y, Feng Z, Zhou S, Luan F, Chen Y. Immune cells dying from ferroptosis: mechanisms and therapeutic opportunities. Cell Death Dis. 2025;16:878.","journal-title":"Cell Death Dis"},{"key":"2688_CR20","doi-asserted-by":"publisher","first-page":"e89160","DOI":"10.1172\/jci.insight.89160","volume":"2","author":"D Howie","year":"2017","unstructured":"Howie D, Cobbold SP, Adams E, Ten Bokum A, Necula AS, Zhang W, Huang H, Roberts DJ, Thomas B, Hester SS, et al. Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. JCI Insight. 2017;2:e89160.","journal-title":"JCI Insight"},{"key":"2688_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12943-025-02460-1","volume":"24","author":"H Zhang","year":"2025","unstructured":"Zhang H, Fan J, Kong D, Sun Y, Zhang Q, Xiang R, Lu S, Yang W, Feng L, Zhang H. Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy. Mol Cancer. 2025;24:249.","journal-title":"Mol Cancer"},{"key":"2688_CR22","doi-asserted-by":"crossref","unstructured":"Perez-Tomas R, Perez-Guillen I. Lactate in the tumor microenvironment: an essential molecule in cancer progression and treatment. Cancers (Basel). 2020;12(11):3244.","DOI":"10.3390\/cancers12113244"},{"key":"2688_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","volume":"40","author":"N Joller","year":"2014","unstructured":"Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, Xia J, Tan TG, Sefik E, Yajnik V, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014;40:569\u201381.","journal-title":"Immunity"},{"key":"2688_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","volume":"24","author":"TS Nowicki","year":"2018","unstructured":"Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J. 2018;24:47\u201353.","journal-title":"Cancer J"},{"key":"2688_CR25","doi-asserted-by":"crossref","unstructured":"Shi Y, Riese DJ 2nd, Shen J. The Role of the CXCL12\/CXCR4\/CXCR7 Chemokine Axis in Cancer. Front Pharmacol. 2020;11:574667.","DOI":"10.3389\/fphar.2020.574667"},{"key":"2688_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.bbrc.2017.05.034","volume":"488","author":"W Liu","year":"2017","unstructured":"Liu W, Wei X, Li L, Wu X, Yan J, Yang H, Song F. CCR4 mediated chemotaxis of regulatory T cells suppress the activation of T cells and NK cells via TGF-beta pathway in human non-small cell lung cancer. Biochem Biophys Res Commun. 2017;488:196\u2013203.","journal-title":"Biochem Biophys Res Commun"},{"key":"2688_CR27","doi-asserted-by":"publisher","first-page":"17945","DOI":"10.1073\/pnas.1316796110","volume":"110","author":"D Sugiyama","year":"2013","unstructured":"Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3\u2009+\u2009CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A. 2013;110:17945\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2688_CR28","doi-asserted-by":"crossref","unstructured":"Marshall LA, Marubayashi S, Jorapur A, Jacobson S, Zibinsky M, Robles O, Hu DX, Jackson JJ, Pookot D, Sanchez J, et al. Tumors establish resistance to immunotherapy by regulating T(reg) recruitment via CCR4. J Immunother Cancer. 2020;8(2):e000764.","DOI":"10.1136\/jitc-2020-000764"},{"key":"2688_CR29","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.ccell.2024.06.014","volume":"42","author":"S You","year":"2024","unstructured":"You S, Li S, Zeng L, Song J, Li Z, Li W, Ni H, Xiao X, Deng W, Li H, et al. Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity. Cancer Cell. 2024;42:1415\u2013e14331412.","journal-title":"Cancer Cell"},{"key":"2688_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.7150\/thno.4922","volume":"3","author":"O Wald","year":"2013","unstructured":"Wald O, Shapira OM, Izhar U. CXCR4\/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics. 2013;3:26\u201333.","journal-title":"Theranostics"},{"key":"2688_CR31","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jtcvs.2012.07.031","volume":"144","author":"D Fahham","year":"2012","unstructured":"Fahham D, Weiss ID, Abraham M, Beider K, Hanna W, Shlomai Z, Eizenberg O, Zamir G, Izhar U, Shapira OM, et al. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer. J Thorac Cardiovasc Surg. 2012;144:1167\u2013e11751161.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2688_CR32","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2020","unstructured":"Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77:1745\u201370.","journal-title":"Cell Mol Life Sci"},{"key":"2688_CR33","doi-asserted-by":"crossref","unstructured":"Sugiyama E, Togashi Y, Takeuchi Y, Shinya S, Tada Y, Kataoka K, Tane K, Sato E, Ishii G, Goto K, et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. Sci Immunol. 2020;5(43):eaav3937.","DOI":"10.1126\/sciimmunol.aav3937"},{"key":"2688_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00262-021-02981-w","volume":"71","author":"J Budczies","year":"2022","unstructured":"Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgauer M, Kriegsmann M, Heussel CP, Herth FJ, Winter H, et al. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunol Immunother. 2022;71:251\u201365.","journal-title":"Cancer Immunol Immunother"},{"key":"2688_CR35","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","volume":"56","author":"MA Moreno Ayala","year":"2023","unstructured":"Moreno Ayala MA, Campbell TF, Zhang C, Dahan N, Bockman A, Prakash V, Feng L, Sher T, DuPage M. CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8(+) T cell antitumor immunity. Immunity. 2023;56:1613\u2013e16301615.","journal-title":"Immunity"},{"key":"2688_CR36","doi-asserted-by":"publisher","first-page":"e1456612","DOI":"10.1080\/2162402X.2018.1456612","volume":"7","author":"K Kachler","year":"2018","unstructured":"Kachler K, Holzinger C, Trufa DI, Sirbu H, Finotto S. The role of Foxp3 and Tbet co-expressing Treg cells in lung carcinoma. Oncoimmunology. 2018;7:e1456612.","journal-title":"Oncoimmunology"},{"key":"2688_CR37","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41586-021-03235-6","volume":"591","author":"SA Lim","year":"2021","unstructured":"Lim SA, Wei J, Nguyen TM, Shi H, Su W, Palacios G, Dhungana Y, Chapman NM, Long L, Saravia J, et al. Lipid signalling enforces functional specialization of T(reg) cells in tumours. Nature. 2021;591:306\u201311.","journal-title":"Nature"},{"key":"2688_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cllc.2020.08.003","volume":"22","author":"M Jahanzeb","year":"2021","unstructured":"Jahanzeb M, Lin HM, Pan X, Yin Y, Baumann P, Langer CJ. Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2021;22:49\u201357.","journal-title":"Clin Lung Cancer"},{"key":"2688_CR39","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30:1321\u20138.","journal-title":"Ann Oncol"},{"key":"2688_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.lungcan.2020.10.009","volume":"150","author":"C Zeng","year":"2020","unstructured":"Zeng C, Gao Y, Xiong J, Lu J, Yang J, Wang X, Cai Y, Li L, Fu X. Tumor-infiltrating CD8(+) T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells. Lung Cancer. 2020;150:139\u201344.","journal-title":"Lung Cancer"},{"key":"2688_CR41","doi-asserted-by":"crossref","unstructured":"Pyo KH, Lim SM, Park CW, Jo HN, Kim JH, Yun MR, Kim D, Xin CF, Lee W, Gheorghiu B et al. Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer. J Immunother Cancer. 2020;8(2):e000970.","DOI":"10.1136\/jitc-2020-000970"},{"key":"2688_CR42","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","volume":"20","author":"DV Sawant","year":"2019","unstructured":"Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, et al. Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019;20:724\u201335.","journal-title":"Nat Immunol"},{"key":"2688_CR43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.immuni.2025.11.014","volume":"59","author":"X Huang","year":"2026","unstructured":"Huang X, Feng D, Mitra S, Andretta ES, Hooshdaran NB, Ghelani AP, Wang EY, Frost JN, Lawless VR, Vancheswaran A, et al. Opposing functions of distinct regulatory T cell subsets in colorectal cancer. Immunity. 2026;59:145\u2013e160149.","journal-title":"Immunity"},{"key":"2688_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/imm.13067","volume":"157","author":"H Yano","year":"2019","unstructured":"Yano H, Andrews LP, Workman CJ, Vignali DAA. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity. Immunology. 2019;157:232\u201347.","journal-title":"Immunology"},{"key":"2688_CR45","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.bbrc.2019.04.152","volume":"514","author":"J Liang","year":"2019","unstructured":"Liang J, Tian C, Zeng Y, Yang Q, Liu Y, Liu Y, Wu J, Hu Y, Gu F, Zhang K, et al. FOXA1(+) regulatory T cells: A novel T cell subset that suppresses antitumor immunity in lung cancer. Biochem Biophys Res Commun. 2019;514:308\u201315.","journal-title":"Biochem Biophys Res Commun"},{"key":"2688_CR46","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41591-018-0045-3","volume":"24","author":"X Guo","year":"2018","unstructured":"Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q, Kang B, Liu Z, Jin L, Xing R, et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med. 2018;24:978\u201385.","journal-title":"Nat Med"},{"key":"2688_CR47","doi-asserted-by":"publisher","first-page":"eadg1487","DOI":"10.1126\/sciimmunol.adg1487","volume":"8","author":"AG Dykema","year":"2023","unstructured":"Dykema AG, Zhang J, Cheung LS, Connor S, Zhang B, Zeng Z, Cherry CM, Li T, Caushi JX, Nishimoto M, et al. Lung tumor-infiltrating T(reg) have divergent transcriptional profiles and function linked to checkpoint blockade response. Sci Immunol. 2023;8:eadg1487.","journal-title":"Sci Immunol"},{"key":"2688_CR48","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1084\/jem.20030152","volume":"198","author":"W Chen","year":"2003","unstructured":"Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4\u2009+\u2009CD25- naive T cells to CD4\u2009+\u2009CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875\u201386.","journal-title":"J Exp Med"},{"key":"2688_CR49","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ni.2499","volume":"14","author":"MG Strainic","year":"2013","unstructured":"Strainic MG, Shevach EM, An F, Lin F, Medof ME. Absence of signaling into CD4(+) cells via C3aR and C5aR enables autoinductive TGF-beta1 signaling and induction of Foxp3(+) regulatory T cells. Nat Immunol. 2013;14:162\u201371.","journal-title":"Nat Immunol"},{"key":"2688_CR50","doi-asserted-by":"publisher","first-page":"6329","DOI":"10.4049\/jimmunol.1100061","volume":"186","author":"Q Chen","year":"2011","unstructured":"Chen Q, Kim YC, Laurence A, Punkosdy GA, Shevach EM. IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3\u2009+\u2009T cells in vivo. J Immunol. 2011;186:6329\u201337.","journal-title":"J Immunol"},{"key":"2688_CR51","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.4049\/jimmunol.178.7.4022","volume":"178","author":"TS Davidson","year":"2007","unstructured":"Davidson TS, DiPaolo RJ, Andersson J, Shevach EM. Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3\u2009+\u2009T regulatory cells. J Immunol. 2007;178:4022\u20136.","journal-title":"J Immunol"},{"key":"2688_CR52","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.4049\/jimmunol.168.9.4272","volume":"168","author":"EY Woo","year":"2002","unstructured":"Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168:4272\u20136.","journal-title":"J Immunol"},{"key":"2688_CR53","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/imr.12172","volume":"259","author":"J Barbi","year":"2014","unstructured":"Barbi J, Pardoll D, Pan F. Treg functional stability and its responsiveness to the microenvironment. Immunol Rev. 2014;259:115\u201339.","journal-title":"Immunol Rev"},{"key":"2688_CR54","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.3389\/fimmu.2019.02716","volume":"10","author":"H Shi","year":"2019","unstructured":"Shi H, Chi H. Metabolic Control of Treg Cell Stability, Plasticity, and Tissue-Specific Heterogeneity. Front Immunol. 2019;10:2716.","journal-title":"Front Immunol"},{"key":"2688_CR55","doi-asserted-by":"publisher","first-page":"13445","DOI":"10.1073\/pnas.0901944106","volume":"106","author":"DQ Tran","year":"2009","unstructured":"Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3\u2009+\u2009regulatory T cells. Proc Natl Acad Sci U S A. 2009;106:13445\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2688_CR56","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nature08750","volume":"463","author":"Y Zheng","year":"2010","unstructured":"Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature. 2010;463:808\u201312.","journal-title":"Nature"},{"key":"2688_CR57","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nature05673","volume":"446","author":"M Ono","year":"2007","unstructured":"Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, Miyachi Y, Tsukada T, Sakaguchi S. Foxp3 controls regulatory T-cell function by interacting with AML1\/Runx1. Nature. 2007;446:685\u20139.","journal-title":"Nature"},{"key":"2688_CR58","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s44318-024-00064-x","volume":"43","author":"Q Wu","year":"2024","unstructured":"Wu Q, Carlos AR, Braza F, Bergman ML, Kitoko JZ, Bastos-Amador P, Cuadrado E, Martins R, Oliveira BS, Martins VC, et al. Ferritin heavy chain supports stability and function of the regulatory T cell lineage. EMBO J. 2024;43:1445\u201383.","journal-title":"EMBO J"},{"key":"2688_CR59","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.cell.2025.11.034","volume":"189","author":"J Gu","year":"2026","unstructured":"Gu J, Li Y, Chen Q, Song Z, Qian Q, Liang Y, Huang T, Qiao L, Li X, Yu M, et al. Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity. Cell. 2026;189:418\u2013e434424.","journal-title":"Cell"},{"key":"2688_CR60","doi-asserted-by":"publisher","first-page":"8813","DOI":"10.7150\/thno.62521","volume":"11","author":"SK Hsu","year":"2021","unstructured":"Hsu SK, Li CY, Lin IL, Syue WJ, Chen YF, Cheng KC, Teng YN, Lin YH, Yen CH, Chiu CC. Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment. Theranostics. 2021;11:8813\u201335.","journal-title":"Theranostics"},{"key":"2688_CR61","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/ni.3365","volume":"17","author":"J Wei","year":"2016","unstructured":"Wei J, Long L, Yang K, Guy C, Shrestha S, Chen Z, Wu C, Vogel P, Neale G, Green DR, Chi H. Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis. Nat Immunol. 2016;17:277\u201385.","journal-title":"Nat Immunol"},{"key":"2688_CR62","doi-asserted-by":"crossref","unstructured":"Pompura SL, Wagner A, Kitz A, LaPerche J, Yosef N, Dominguez-Villar M, Hafler DA. Oleic acid restores suppressive defects in tissue-resident FOXP3 Tregs from patients with multiple sclerosis. J Clin Invest. 2021;131(2):e138519.","DOI":"10.1172\/JCI138519"},{"key":"2688_CR63","doi-asserted-by":"crossref","unstructured":"Bai J, Yan M, Xu Y, Wang Y, Yao Y, Jin P, Zhang Y, Qu Y, Niu L, Li H. YAP enhances mitochondrial OXPHOS in tumor-infiltrating Treg through upregulating Lars2 on stiff matrix. J Immunother Cancer. 2024;12(11):e010463.","DOI":"10.1136\/jitc-2024-010463"},{"key":"2688_CR64","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.immuni.2020.06.016","volume":"53","author":"S Kumagai","year":"2020","unstructured":"Kumagai S, Togashi Y, Sakai C, Kawazoe A, Kawazu M, Ueno T, Sato E, Kuwata T, Kinoshita T, Yamamoto M, et al. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. Immunity. 2020;53:187\u2013e203188.","journal-title":"Immunity"},{"key":"2688_CR65","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00432-022-03957-8","volume":"148","author":"C Ruan","year":"2022","unstructured":"Ruan C, Meng Y, Song H. CD36: an emerging therapeutic target for cancer and its molecular mechanisms. J Cancer Res Clin Oncol. 2022;148:1551\u20138.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2688_CR66","doi-asserted-by":"publisher","first-page":"E6546","DOI":"10.1073\/pnas.1720113115","volume":"115","author":"I Pacella","year":"2018","unstructured":"Pacella I, Procaccini C, Focaccetti C, Miacci S, Timperi E, Faicchia D, Severa M, Rizzo F, Coccia EM, Bonacina F, et al. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc Natl Acad Sci U S A. 2018;115:E6546\u201355.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2688_CR67","doi-asserted-by":"publisher","first-page":"eaaw6443","DOI":"10.1126\/sciadv.aaw6443","volume":"6","author":"J Saravia","year":"2020","unstructured":"Saravia J, Zeng H, Dhungana Y, Bastardo Blanco D, Nguyen TM, Chapman NM, Wang Y, Kanneganti A, Liu S, Raynor JL, et al. Homeostasis and transitional activation of regulatory T cells require c-Myc. Sci Adv. 2020;6:eaaw6443.","journal-title":"Sci Adv"},{"key":"2688_CR68","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","volume":"591","author":"R Zappasodi","year":"2021","unstructured":"Zappasodi R, Serganova I, Cohen IJ, Maeda M, Shindo M, Senbabaoglu Y, Watson MJ, Leftin A, Maniyar R, Verma S, et al. CTLA-4 blockade drives loss of T(reg) stability in glycolysis-low tumours. Nature. 2021;591:652\u20138.","journal-title":"Nature"},{"key":"2688_CR69","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","volume":"40","author":"S Kumagai","year":"2022","unstructured":"Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022;40:201\u2013e218209.","journal-title":"Cancer Cell"},{"key":"2688_CR70","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","volume":"591","author":"MJ Watson","year":"2021","unstructured":"Watson MJ, Vignali PDA, Mullett SJ, Overacre-Delgoffe AE, Peralta RM, Grebinoski S, Menk AV, Rittenhouse NL, DePeaux K, Whetstone RD, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021;591:645\u201351.","journal-title":"Nature"},{"key":"2688_CR71","doi-asserted-by":"crossref","unstructured":"Castillo JG, Silveria S, Sauquet A, Schirokauer L, Hendricks J, Sul HS, Olzmann JA, DuPage M. Selective disruption of lipid peroxide homeostasis in intratumoral regulatory T cells by targeting FSP1 enhances cancer immunity. bioRxiv. 2025;12(4):eaea3703.","DOI":"10.1126\/sciadv.aea3703"},{"key":"2688_CR72","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cmet.2024.10.015","volume":"37","author":"R Zhu","year":"2025","unstructured":"Zhu R, Ye X, Lu X, Xiao L, Yuan M, Zhao H, Guo D, Meng Y, Han H, Luo S, et al. ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion. Cell Metab. 2025;37:361\u2013e376367.","journal-title":"Cell Metab"},{"key":"2688_CR73","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/00365521.2023.2301331","volume":"59","author":"Z Xu","year":"2024","unstructured":"Xu Z, Wang X, Yu P, Zhang Y, Huang L, Mao E, Han Y. Lysine acetyltransferase KAT2A modulates ferroptosis during colorectal cancer development. Scand J Gastroenterol. 2024;59:437\u201344.","journal-title":"Scand J Gastroenterol"},{"key":"2688_CR74","doi-asserted-by":"publisher","first-page":"113995","DOI":"10.1016\/j.celrep.2024.113995","volume":"43","author":"Z Zou","year":"2024","unstructured":"Zou Z, Cheng Q, Zhou J, Guo C, Hadjinicolaou AV, Salio M, Liang X, Yang C, Du Y, Yao W, et al. ATF4-SLC7A11-GSH axis mediates the acquisition of immunosuppressive properties by activated CD4(+) T cells in low arginine condition. Cell Rep. 2024;43:113995.","journal-title":"Cell Rep"},{"key":"2688_CR75","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20062512","volume":"204","author":"S Deaglio","year":"2007","unstructured":"Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257\u201365.","journal-title":"J Exp Med"},{"key":"2688_CR76","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/ni.3868","volume":"18","author":"T Maj","year":"2017","unstructured":"Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S, Zhao L, Vatan L, Shao I, Szeliga W, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol. 2017;18:1332\u201341.","journal-title":"Nat Immunol"},{"key":"2688_CR77","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0065-230X(10)07003-X","volume":"107","author":"D Mougiakakos","year":"2010","unstructured":"Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory T cells in cancer. Adv Cancer Res. 2010;107:57\u2013117.","journal-title":"Adv Cancer Res"},{"key":"2688_CR78","doi-asserted-by":"publisher","first-page":"E10672","DOI":"10.1073\/pnas.1810580115","volume":"115","author":"AM Magnuson","year":"2018","unstructured":"Magnuson AM, Kiner E, Ergun A, Park JS, Asinovski N, Ortiz-Lopez A, Kilcoyne A, Paoluzzi-Tomada E, Weissleder R, Mathis D, Benoist C. Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types. Proc Natl Acad Sci U S A. 2018;115:E10672\u201381.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2688_CR79","doi-asserted-by":"crossref","unstructured":"Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8:e000957.","DOI":"10.1136\/jitc-2020-000957"},{"key":"2688_CR80","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.immuni.2019.12.002","volume":"52","author":"M Delacher","year":"2020","unstructured":"Delacher M, Imbusch CD, Hotz-Wagenblatt A, Mallm JP, Bauer K, Simon M, Riegel D, Rendeiro AF, Bittner S, Sanderink L, et al. Precursors for Nonlymphoid-Tissue Treg Cells Reside in Secondary Lymphoid Organs and Are Programmed by the Transcription Factor BATF. Immunity. 2020;52:295\u2013e312211.","journal-title":"Immunity"},{"key":"2688_CR81","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/ni.3085","volume":"16","author":"A Vasanthakumar","year":"2015","unstructured":"Vasanthakumar A, Moro K, Xin A, Liao Y, Gloury R, Kawamoto S, Fagarasan S, Mielke LA, Afshar-Sterle S, Masters SL, et al. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat Immunol. 2015;16:276\u201385.","journal-title":"Nat Immunol"},{"key":"2688_CR82","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1172\/JCI130426","volume":"130","author":"G Alvisi","year":"2020","unstructured":"Alvisi G, Brummelman J, Puccio S, Mazza EM, Tomada EP, Losurdo A, Zanon V, Peano C, Colombo FS, Scarpa A, et al. IRF4 instructs effector Treg differentiation and immune suppression in human cancer. J Clin Invest. 2020;130:3137\u201350.","journal-title":"J Clin Invest"},{"key":"2688_CR83","doi-asserted-by":"publisher","first-page":"eaea3703","DOI":"10.1126\/sciadv.aea3703","volume":"12","author":"JG Castillo","year":"2026","unstructured":"Castillo JG, Silveria S, Schirokauer L, Sauquet A, Hung J, Jaworski G, Hendricks JM, Sul HS, Olzmann JA, DuPage M. Selective disruption of lipid peroxide homeostasis in intratumoral regulatory T cells by targeting FSP1 enhances cancer immunity. Sci Adv. 2026;12:eaea3703.","journal-title":"Sci Adv"},{"key":"2688_CR84","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","volume":"1","author":"PS Linsley","year":"1994","unstructured":"Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994;1:793\u2013801.","journal-title":"Immunity"},{"key":"2688_CR85","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","volume":"182","author":"MF Krummel","year":"1995","unstructured":"Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459\u201365.","journal-title":"J Exp Med"},{"key":"2688_CR86","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","volume":"332","author":"OS Qureshi","year":"2011","unstructured":"Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332:600\u20133.","journal-title":"Science"},{"key":"2688_CR87","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.3746","volume":"20","author":"D Schubert","year":"2014","unstructured":"Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, Bulashevska A, Petersen BS, Schaffer AA, Gruning BA, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20:1410\u20136.","journal-title":"Nat Med"},{"key":"2688_CR88","doi-asserted-by":"crossref","unstructured":"Kong KF, Fu G, Zhang Y, Yokosuka T, Casas J, Canonigo-Balancio AJ, Becart S, Kim G, Yates JR 3rd, Kronenberg M, et al. Protein kinase C-eta controls CTLA-4-mediated regulatory T cell function. Nat Immunol. 2014;15:465\u201372.","DOI":"10.1038\/ni.2866"},{"key":"2688_CR89","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1084\/jem.20050783","volume":"203","author":"CE Tadokoro","year":"2006","unstructured":"Tadokoro CE, Shakhar G, Shen S, Ding Y, Lino AC, Maraver A, Lafaille JJ, Dustin ML. Regulatory T cells inhibit stable contacts between CD4\u2009+\u2009T cells and dendritic cells in vivo. J Exp Med. 2006;203:505\u201311.","journal-title":"J Exp Med"},{"key":"2688_CR90","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.4049\/jimmunol.158.5.1989","volume":"158","author":"JA Bluestone","year":"1997","unstructured":"Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol. 1997;158:1989\u201393.","journal-title":"J Immunol"},{"key":"2688_CR91","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1084\/jem.192.2.303","volume":"192","author":"T Takahashi","year":"2000","unstructured":"Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303\u201310.","journal-title":"J Exp Med"},{"key":"2688_CR92","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","volume":"21","author":"CT Huang","year":"2004","unstructured":"Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21:503\u201313.","journal-title":"Immunity"},{"key":"2688_CR93","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.immuni.2023.01.010","volume":"56","author":"M Zagorulya","year":"2023","unstructured":"Zagorulya M, Yim L, Morgan DM, Edwards A, Torres-Mejia E, Momin N, McCreery CV, Zamora IL, Horton BL, Fox JG, et al. Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer. Immunity. 2023;56:386\u2013e405310.","journal-title":"Immunity"},{"key":"2688_CR94","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DA Vignali","year":"2008","unstructured":"Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523\u201332.","journal-title":"Nat Rev Immunol"},{"key":"2688_CR95","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1073\/pnas.0408197102","volume":"102","author":"ML Chen","year":"2005","unstructured":"Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, Khazaie K. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A. 2005;102:419\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2688_CR96","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1084\/jem.20050463","volume":"202","author":"F Ghiringhelli","year":"2005","unstructured":"Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, Kroemer G, Martin F, Chauffert B, Zitvogel L. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4\u2009+\u2009CD25+ regulatory T cell proliferation. J Exp Med. 2005;202:919\u201329.","journal-title":"J Exp Med"},{"key":"2688_CR97","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1073\/pnas.0707370105","volume":"105","author":"SL Fink","year":"2008","unstructured":"Fink SL, Bergsbaken T, Cookson BT. Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms. Proc Natl Acad Sci U S A. 2008;105:4312\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2688_CR98","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057\u201361.","journal-title":"Science"},{"key":"2688_CR99","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4\u2009+\u2009CD25+ regulatory T cells. Nat Immunol. 2003;4:330\u20136.","journal-title":"Nat Immunol"},{"key":"2688_CR100","doi-asserted-by":"publisher","first-page":"7129","DOI":"10.4049\/jimmunol.1090105","volume":"185","author":"J Verhagen","year":"2010","unstructured":"Verhagen J, Wraith DC. Comment on Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3\u2009+\u2009T regulatory cells. J Immunol. 2010;185:7129. author reply 7130.","journal-title":"J Immunol"},{"key":"2688_CR101","doi-asserted-by":"publisher","first-page":"e0141161","DOI":"10.1371\/journal.pone.0141161","volume":"10","author":"E Szurek","year":"2015","unstructured":"Szurek E, Cebula A, Wojciech L, Pietrzak M, Rempala G, Kisielow P, Ignatowicz L. Differences in Expression Level of Helios and Neuropilin-1 Do Not Distinguish Thymus-Derived from Extrathymically-Induced CD4\u2009+\u2009Foxp3+ Regulatory T Cells. PLoS ONE. 2015;10:e0141161.","journal-title":"PLoS ONE"},{"key":"2688_CR102","doi-asserted-by":"publisher","first-page":"976","DOI":"10.4049\/jimmunol.1102964","volume":"188","author":"RA Gottschalk","year":"2012","unstructured":"Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced Foxp3\u2009+\u2009regulatory T cells. J Immunol. 2012;188:976\u201380.","journal-title":"J Immunol"},{"key":"2688_CR103","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/exd.12711","volume":"24","author":"K Sugita","year":"2015","unstructured":"Sugita K, Hanakawa S, Honda T, Kondoh G, Miyachi Y, Kabashima K, Nomura T. Generation of Helios reporter mice and an evaluation of the suppressive capacity of Helios(+) regulatory T cells in vitro. Exp Dermatol. 2015;24:554\u20136.","journal-title":"Exp Dermatol"},{"key":"2688_CR104","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1371\/journal.pbio.0050038","volume":"5","author":"S Floess","year":"2007","unstructured":"Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang HD, Bopp T, Schmitt E, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007;5:e38.","journal-title":"PLoS Biol"},{"key":"2688_CR105","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/eji.201847935","volume":"49","author":"AM Thornton","year":"2019","unstructured":"Thornton AM, Lu J, Korty PE, Kim YC, Martens C, Sun PD, Shevach EM. Helios(+) and Helios(-) Treg subpopulations are phenotypically and functionally distinct and express dissimilar TCR repertoires. Eur J Immunol. 2019;49:398\u2013412.","journal-title":"Eur J Immunol"},{"key":"2688_CR106","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1084\/jem.20131142","volume":"211","author":"KS Smigiel","year":"2014","unstructured":"Smigiel KS, Richards E, Srivastava S, Thomas KR, Dudda JC, Klonowski KD, Campbell DJ. CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets. J Exp Med. 2014;211:121\u201336.","journal-title":"J Exp Med"},{"key":"2688_CR107","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20040179","volume":"199","author":"AE Herman","year":"2004","unstructured":"Herman AE, Freeman GJ, Mathis D, Benoist C. CD4\u2009+\u2009CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med. 2004;199:1479\u201389.","journal-title":"J Exp Med"},{"key":"2688_CR108","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1182\/blood-2011-11-392324","volume":"119","author":"T Duhen","year":"2012","unstructured":"Duhen T, Duhen R, Lanzavecchia A, Sallusto F, Campbell DJ. Functionally distinct subsets of human FOXP3\u2009+\u2009Treg cells that phenotypically mirror effector Th cells. Blood. 2012;119:4430\u201340.","journal-title":"Blood"},{"key":"2688_CR109","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.biopha.2017.08.003","volume":"95","author":"X Liu","year":"2017","unstructured":"Liu X, Wu S, Yang Y, Zhao M, Zhu G, Hou Z. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacother. 2017;95:55\u201361.","journal-title":"Biomed Pharmacother"},{"key":"2688_CR110","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1073\/pnas.1621280114","volume":"114","author":"Y Barsheshet","year":"2017","unstructured":"Barsheshet Y, Wildbaum G, Levy E, Vitenshtein A, Akinseye C, Griggs J, Lira SA, Karin N. CCR8(+)FOXp3(+) T(reg) cells as master drivers of immune regulation. Proc Natl Acad Sci U S A. 2017;114:6086\u201391.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2688_CR111","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A. 2019;116:9999\u201310008.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2688_CR112","doi-asserted-by":"publisher","first-page":"eadl6464","DOI":"10.1126\/sciadv.adl6464","volume":"10","author":"M Cole","year":"2024","unstructured":"Cole M, Anastasiou P, Lee C, Yu X, de Castro A, Roelink J, Moore C, Mugarza E, Jones M, Valand K, et al. Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses. Sci Adv. 2024;10:eadl6464.","journal-title":"Sci Adv"},{"key":"2688_CR113","doi-asserted-by":"publisher","first-page":"eabn6173","DOI":"10.1126\/sciimmunol.abn6173","volume":"8","author":"M van Gulijk","year":"2023","unstructured":"van Gulijk M, van Krimpen A, Schetters S, Eterman M, van Elsas M, Mankor J, Klaase L, de Bruijn M, van Nimwegen M, van Tienhoven T, et al. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Sci Immunol. 2023;8:eabn6173.","journal-title":"Sci Immunol"},{"key":"2688_CR114","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","volume":"21","author":"S Kumagai","year":"2020","unstructured":"Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21:1346\u201358.","journal-title":"Nat Immunol"},{"key":"2688_CR115","doi-asserted-by":"crossref","unstructured":"Kim HR, Park HJ, Son J, Lee JG, Chung KY, Cho NH, Shim HS, Park S, Kim G, et al. In Yoon H, : Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. J Immunother Cancer. 2019;7(1):339.","DOI":"10.1186\/s40425-019-0785-8"},{"key":"2688_CR116","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.jtho.2025.02.029","volume":"20","author":"P Chen","year":"2025","unstructured":"Chen P, Wang H, Tang Z, Shi J, Cheng L, Zhao C, Li X, Zhou C. Selective Depletion of CCR8\u2009+\u2009Treg Cells Enhances the Antitumor Immunity of Cytotoxic T Cells in Lung Cancer by Dendritic Cells. J Thorac Oncol. 2025;20:1050\u201374.","journal-title":"J Thorac Oncol"},{"key":"2688_CR117","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","volume":"33","author":"X Ma","year":"2021","unstructured":"Ma X, Xiao L, Liu L, Ye L, Su P, Bi E, Wang Q, Yang M, Qian J, Yi Q. CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability. Cell Metab. 2021;33:1001\u2013e10121005.","journal-title":"Cell Metab"},{"key":"2688_CR118","doi-asserted-by":"crossref","unstructured":"Chen S, Fan J, Xie P, Ahn J, Fernandez M, Billingham LK, Miska J, Wu JD, Wainwright DA, Fang D, et al. CD8\u2009+\u2009T cells sustain antitumor response by mediating crosstalk between adenosine A2A receptor and glutathione\/GPX4. J Clin Invest. 2024;134(8):e170071.","DOI":"10.1172\/JCI170071"},{"key":"2688_CR119","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.celrep.2019.03.037","volume":"27","author":"L DeVorkin","year":"2019","unstructured":"DeVorkin L, Pavey N, Carleton G, Comber A, Ho C, Lim J, McNamara E, Huang H, Kim P, Zacharias LG, et al. Autophagy Regulation of Metabolism Is Required for CD8(+) T Cell Anti-tumor Immunity. Cell Rep. 2019;27:502\u2013e513505.","journal-title":"Cell Rep"},{"key":"2688_CR120","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s13046-019-1420-8","volume":"38","author":"C D\u2019Alterio","year":"2019","unstructured":"D\u2019Alterio C, Buoncervello M, Ieran\u00f2 C, Napolitano M, Portella L, Rea G, Barbieri A, Luciano A, Scognamiglio G, Tatangelo F, et al. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. J Exp Clin Cancer Res. 2019;38:432.","journal-title":"J Exp Clin Cancer Res"},{"key":"2688_CR121","doi-asserted-by":"crossref","unstructured":"Azar F, Deforges J, Demeusoit C, Kleinpeter P, Remy C, Silvestre N, Foloppe J, Fend L, Spring-Giusti C, Qu\u00e9m\u00e9neur E, Marchand JB. TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment. J Immunother Cancer. 2024;12(7):e009302.","DOI":"10.1136\/jitc-2024-009302"},{"key":"2688_CR122","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-021-03651-8","volume":"595","author":"M Casanova-Acebes","year":"2021","unstructured":"Casanova-Acebes M, Dalla E, Leader AM, LeBerichel J, Nikolic J, Morales BM, Brown M, Chang C, Troncoso L, Chen ST, et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature. 2021;595:578\u201384.","journal-title":"Nature"},{"key":"2688_CR123","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/JTO.0b013e31820b80ca","volume":"6","author":"T Schneider","year":"2011","unstructured":"Schneider T, Kimpfler S, Warth A, Schnabel PA, Dienemann H, Schadendorf D, Hoffmann H, Umansky V. Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol. 2011;6:432\u20138.","journal-title":"J Thorac Oncol"},{"key":"2688_CR124","doi-asserted-by":"crossref","unstructured":"Koppensteiner L, Mathieson L, Pattle S, Dorward DA, O\u2019Connor R, Akram AR. Location of CD39(+) T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer. J Immunother Cancer. 2023;11(8):e006770.","DOI":"10.1136\/jitc-2023-006770"},{"key":"2688_CR125","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12943-025-02287-w","volume":"24","author":"X Cui","year":"2025","unstructured":"Cui X, Liu S, Song H, Xu J, Sun Y. Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Mol Cancer. 2025;24:111.","journal-title":"Mol Cancer"},{"key":"2688_CR126","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.ccell.2023.03.009","volume":"41","author":"JA Pai","year":"2023","unstructured":"Pai JA, Hellmann MD, Sauter JL, Mattar M, Rizvi H, Woo HJ, Shah N, Nguyen EM, Uddin FZ, Quintanal-Villalonga A, et al. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. Cancer Cell. 2023;41:776\u2013e790777.","journal-title":"Cancer Cell"},{"key":"2688_CR127","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.imlet.2019.10.007","volume":"217","author":"B Sun","year":"2020","unstructured":"Sun B, Liu M, Cui M, Li T. Granzyme B-expressing treg cells are enriched in colorectal cancer and present the potential to eliminate autologous T conventional cells. Immunol Lett. 2020;217:7\u201314.","journal-title":"Immunol Lett"},{"key":"2688_CR128","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41590-024-01792-2","volume":"25","author":"JH Chen","year":"2024","unstructured":"Chen JH, Nieman LT, Spurrell M, Jorgji V, Elmelech L, Richieri P, Xu KH, Madhu R, Parikh M, Zamora I, et al. Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy. Nat Immunol. 2024;25:644\u201358.","journal-title":"Nat Immunol"},{"key":"2688_CR129","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41423-021-00742-4","volume":"19","author":"LA Huppert","year":"2022","unstructured":"Huppert LA, Green MD, Kim L, Chow C, Leyfman Y, Daud AI, Lee JC. Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. Cell Mol Immunol. 2022;19:33\u201345.","journal-title":"Cell Mol Immunol"},{"key":"2688_CR130","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2011.06.002","volume":"75","author":"H Tao","year":"2012","unstructured":"Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, Okabe K, Matsumoto T, Sugi K, Ueoka H. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2012;75:95\u2013101.","journal-title":"Lung Cancer"},{"key":"2688_CR131","doi-asserted-by":"publisher","first-page":"E928","DOI":"10.1002\/ijc.27613","volume":"131","author":"W Wang","year":"2012","unstructured":"Wang W, Hodkinson P, McLaren F, MacKinnon A, Wallace W, Howie S, Sethi T. Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3\u2009+\u2009cells in tumour infiltrate. Int J Cancer. 2012;131:E928\u2013937.","journal-title":"Int J Cancer"},{"key":"2688_CR132","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1158\/1078-0432.CCR-23-0251","volume":"30","author":"ER Parra","year":"2024","unstructured":"Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, et al. Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial. Clin Cancer Res. 2024;30:1655\u201368.","journal-title":"Clin Cancer Res"},{"key":"2688_CR133","doi-asserted-by":"publisher","first-page":"101934","DOI":"10.1016\/j.xcrm.2025.101934","volume":"6","author":"F Peyraud","year":"2025","unstructured":"Peyraud F, Gu\u00e9gan JP, Rey C, Lara O, Odin O, Del Castillo M, Vanhersecke L, Coindre JM, Clot E, Brunet M, et al. Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures. Cell Rep Med. 2025;6:101934.","journal-title":"Cell Rep Med"},{"key":"2688_CR134","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.immuni.2016.09.009","volume":"45","author":"R Daill\u00e8re","year":"2016","unstructured":"Daill\u00e8re R, V\u00e9tizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, Duong CPM, Flament C, Lepage P, Roberti MP, et al. Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity. 2016;45:931\u201343.","journal-title":"Immunity"},{"key":"2688_CR135","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1158\/1078-0432.CCR-22-2566","volume":"29","author":"HS Lee","year":"2023","unstructured":"Lee HS, Jang HJ, Ramineni M, Wang DY, Ramos D, Choi JM, Splawn T, Espinoza M, Almarez M, Hosey L, et al. A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2023;29:548\u201359.","journal-title":"Clin Cancer Res"},{"key":"2688_CR136","doi-asserted-by":"publisher","first-page":"eabk0957","DOI":"10.1126\/sciimmunol.abk0957","volume":"7","author":"K Itahashi","year":"2022","unstructured":"Itahashi K, Irie T, Yuda J, Kumagai S, Tanegashima T, Lin YT, Watanabe S, Goto Y, Suzuki J, Aokage K, et al. BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Sci Immunol. 2022;7:eabk0957.","journal-title":"Sci Immunol"},{"key":"2688_CR137","doi-asserted-by":"crossref","unstructured":"Ao YQ, Gao J, Jin C, Wang S, Zhang LC, Deng J, Chen ZW, Wang HK, Jiang JH, Ding JY. ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3. J Immunother Cancer. 2023;11(12):e007766.","DOI":"10.1136\/jitc-2023-007766"},{"key":"2688_CR138","doi-asserted-by":"crossref","unstructured":"Marwitz S, Ballesteros-Merino C, Jensen SM, Reck M, Kugler C, Perner S, Dr\u00f6mann D, Goldmann T, Fox BA. Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer. J Immunother Cancer. 2021;9(2):e001469.","DOI":"10.1136\/jitc-2020-001469"},{"key":"2688_CR139","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/ajh.25627","volume":"94","author":"IM Ghobrial","year":"2019","unstructured":"Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, et al. Phase I\/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed\/refractory multiple myeloma. Am J Hematol. 2019;94:1244\u201353.","journal-title":"Am J Hematol"},{"key":"2688_CR140","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.1039\/C9BM01418G","volume":"7","author":"J Jiang","year":"2019","unstructured":"Jiang J, Shen N, Song W, Yu H, Sakurai K, Tang Z, Li G. Combretastatin A4 nanodrug combined plerixafor for inhibiting tumor growth and metastasis simultaneously. Biomater Sci. 2019;7:5283\u201391.","journal-title":"Biomater Sci"},{"key":"2688_CR141","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s40425-019-0815-6","volume":"7","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Pishvaian MJ, Shepard DR, Wang D, Weiss J, Johnson ML, Chung CH, Chen Y, Huang B, Davis CB, et al. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. J Immunother Cancer. 2019;7:342.","journal-title":"J Immunother Cancer"},{"key":"2688_CR142","doi-asserted-by":"crossref","unstructured":"Noyes D, Bag A, Oseni S, Semidey-Hurtado J, Cen L, Sarnaik AA, Sondak VK, Adeegbe D. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8\u2009+\u2009T cells. J Immunother Cancer. 2022;10(5):e004605.","DOI":"10.1136\/jitc-2022-004605"},{"key":"2688_CR143","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/2159-8290.CD-24-1409","volume":"15","author":"SF Tzeng","year":"2025","unstructured":"Tzeng SF, Yu YR, Park J, von Renesse J, Hsiao HW, Hsu CH, Garnica J, Chen J, Chiu LT, Santol J, et al. PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis. Cancer Discov. 2025;15:1676\u201396.","journal-title":"Cancer Discov"},{"key":"2688_CR144","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ebiom.2019.10.044","volume":"49","author":"J Pan","year":"2019","unstructured":"Pan J, Zhang Q, Palen K, Wang L, Qiao L, Johnson B, Sei S, Shoemaker RH, Lubet RA, Wang Y, You M. Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator. EBioMedicine. 2019;49:72\u201381.","journal-title":"EBioMedicine"},{"key":"2688_CR145","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1080\/15548627.2024.2411854","volume":"20","author":"L Mont\u00e9gut","year":"2024","unstructured":"Mont\u00e9gut L, Martins I, Kroemer G. Neutralization of the autophagy-repressive tissue hormone DBI\/ACBP (diazepam binding inhibitor, acyl-CoA binding protein) enhances anticancer immunosurveillance. Autophagy. 2024;20:2836\u20138.","journal-title":"Autophagy"},{"key":"2688_CR146","doi-asserted-by":"publisher","first-page":"e2105885","DOI":"10.1002\/advs.202105885","volume":"9","author":"M Huang","year":"2022","unstructured":"Huang M, Xiong D, Pan J, Zhang Q, Sei S, Shoemaker RH, Lubet RA, Montuenga LM, Wang Y, Slusher BS, You M. Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer. Adv Sci (Weinh). 2022;9:e2105885.","journal-title":"Adv Sci (Weinh)"},{"key":"2688_CR147","doi-asserted-by":"publisher","first-page":"e2503208","DOI":"10.1002\/smll.202503208","volume":"21","author":"C Jiang","year":"2025","unstructured":"Jiang C, Li X, Wan S, Ji S, Wang Q, Hu S, Chen P, Wang B, Ge T, Zhang J, et al. Copper-Doped Polydopamine Nanoparticles-Mediated GSH\/GPX4-Depleted Ferroptosis and Cuproptosis Sensitizes Lung Tumor to Checkpoint Blockade Immunotherapy. Small. 2025;21:e2503208.","journal-title":"Small"},{"key":"2688_CR148","doi-asserted-by":"publisher","first-page":"157660","DOI":"10.1016\/j.phymed.2025.157660","volume":"150","author":"T Xu","year":"2026","unstructured":"Xu T, Liu Q, Ma H, Xu M, Zhang J, Wang Y, Xu D, Zhao X, Liu L, Yan Z, et al. Tubeimoside II potentiates anti-PD-1 therapy in NSCLC by increasing ferroptosis sensitivity and remodeling immune landscape. Phytomedicine. 2026;150:157660.","journal-title":"Phytomedicine"},{"key":"2688_CR149","doi-asserted-by":"publisher","first-page":"340","DOI":"10.7150\/thno.65522","volume":"12","author":"PS Yang","year":"2022","unstructured":"Yang PS, Yu MH, Hou YC, Chang CP, Lin SC, Kuo IY, Su PC, Cheng HC, Su WC, Shan YS, Wang YC. Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy. Theranostics. 2022;12:340\u201361.","journal-title":"Theranostics"},{"key":"2688_CR150","doi-asserted-by":"publisher","first-page":"eadh8005","DOI":"10.1126\/scitranslmed.adh8005","volume":"15","author":"BH Herzog","year":"2023","unstructured":"Herzog BH, Baer JM, Borcherding N, Kingston NL, Belle JI, Knolhoff BL, Hogg GD, Ahmad F, Kang LI, Petrone J, et al. Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer. Sci Transl Med. 2023;15:eadh8005.","journal-title":"Sci Transl Med"},{"key":"2688_CR151","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","volume":"182","author":"A Maynard","year":"2020","unstructured":"Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, et al. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell. 2020;182:1232\u2013e12511222.","journal-title":"Cell"},{"key":"2688_CR152","doi-asserted-by":"publisher","first-page":"101176","DOI":"10.1016\/j.drup.2024.101176","volume":"78","author":"D Wu","year":"2025","unstructured":"Wu D, Sun Q, Tang H, Xiao H, Luo J, Ouyang L, Sun Q. Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies. Drug Resist Updat. 2025;78:101176.","journal-title":"Drug Resist Updat"},{"key":"2688_CR153","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.21037\/jtd-2025-97","volume":"17","author":"Z Huang","year":"2025","unstructured":"Huang Z, Wu Y, Ye H, Wang Y, Huang Z, Chen Y, Cheng Z, Huang X, Xiao C, Li J, et al. Prediction of the efficacy and clinical prognosis of first-line EGFR-tyrosine kinase inhibitors in non-small cell lung cancer patients based on DeltaCt values derived from the super-amplification refractory mutation system (ARMS): a real-world retrospective study. J Thorac Dis. 2025;17:3897\u2013911.","journal-title":"J Thorac Dis"},{"key":"2688_CR154","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1093\/neuonc\/noaf183","volume":"27","author":"Y Pina","year":"2025","unstructured":"Pina Y, Law V, Sahebjam S, Tran N, Siddarajappa N, Li J, Mo Q, Phadke MS, Arrington J, Macaulay R, et al. Phase IB study of Avelumab and whole brain radiotherapy in patients with leptomeningeal disease from solid tumors: Results and molecular analyses. Neuro Oncol. 2025;27:3237\u201349.","journal-title":"Neuro Oncol"},{"key":"2688_CR155","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40478-025-01939-8","volume":"13","author":"M Kleinberger","year":"2025","unstructured":"Kleinberger M, Cifci D, Paiato C, Tomasich E, Mair MJ, Steindl A, Spiro Z, Carrero ZI, Berchtold L, Hainfellner J, et al. Density and entropy of immune cells within the tumor microenvironment of primary tumors and matched brain metastases. Acta Neuropathol Commun. 2025;13:34.","journal-title":"Acta Neuropathol Commun"},{"key":"2688_CR156","first-page":"100230","volume":"2","author":"D Ikarashi","year":"2021","unstructured":"Ikarashi D, Okimoto T, Shukuya T, Onagi H, Hayashi T, Sinicropi-Yao SL, Amann JM, Nakatsura T, Kitano S, Carbone DP. Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC. JTO Clin Res Rep. 2021;2:100230.","journal-title":"JTO Clin Res Rep"},{"key":"2688_CR157","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41698-021-00151-w","volume":"5","author":"T Jiang","year":"2021","unstructured":"Jiang T, Yan Y, Zhou K, Su C, Ren S, Li N, Hou L, Guo X, Zhu W, Zhang H, et al. Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma. NPJ Precis Oncol. 2021;5:6.","journal-title":"NPJ Precis Oncol"},{"key":"2688_CR158","doi-asserted-by":"crossref","unstructured":"Tashiro T, Imamura K, Tomita Y, Tamanoi D, Takaki A, Sugahara K, Sato R, Saruwatari K, Sakata S, Inaba M, et al. Heterogeneous tumor-immune microenvironments between primary and metastatic tumors in a patient with ALK rearrangement-positive large cell neuroendocrine carcinoma. Int J Mol Sci. 2020;21(24):9705.","DOI":"10.3390\/ijms21249705"},{"key":"2688_CR159","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40164-024-00574-8","volume":"13","author":"F Meng","year":"2024","unstructured":"Meng F, Li H, Jin R, Yang A, Luo H, Li X, Wang P, Zhao Y, Chervova O, Tang K, et al. Spatial immunogenomic patterns associated with lymph node metastasis in lung adenocarcinoma. Exp Hematol Oncol. 2024;13:106.","journal-title":"Exp Hematol Oncol"},{"key":"2688_CR160","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1158\/0008-5472.CAN-20-1885","volume":"81","author":"L La Fleur","year":"2021","unstructured":"La Fleur L, Botling J, He F, Pelicano C, Zhou C, He C, Palano G, Mezheyeuski A, Micke P, Ravetch JV, et al. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function. Cancer Res. 2021;81:956\u201367.","journal-title":"Cancer Res"},{"key":"2688_CR161","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.21037\/tlcr-2025-274","volume":"14","author":"AH Zheng","year":"2025","unstructured":"Zheng AH, Yu C, Su YR, Peng M, Chen JY, Wang FW, Zhu XM, Yan PY, Wang HT, Shen J, et al. Immunotherapy with lymphocytes derived from banked tumor tissue in two refractory NSCLC patients with leptomeningeal metastases: a report of two cases. Transl Lung Cancer Res. 2025;14:2880\u201390.","journal-title":"Transl Lung Cancer Res"},{"key":"2688_CR162","doi-asserted-by":"crossref","unstructured":"Huang SW, Lai YG, Liao HT, Chang CL, Ma RY, Chen YH, Liou YH, Wu ZQ, Wu YC, Liu KJ, et al. Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases. Elife. 2025;13:RP99010.","DOI":"10.7554\/eLife.99010"},{"key":"2688_CR163","doi-asserted-by":"publisher","first-page":"107924","DOI":"10.1016\/j.intimp.2021.107924","volume":"99","author":"N Zhao","year":"2021","unstructured":"Zhao N, Zhu W, Wang J, Liu W, Kang L, Yu R, Liu B. Group 2 innate lymphoid cells promote TNBC lung metastasis via the IL-13-MDSC axis in a murine tumor model. Int Immunopharmacol. 2021;99:107924.","journal-title":"Int Immunopharmacol"},{"key":"2688_CR164","doi-asserted-by":"crossref","unstructured":"Kratzmeier C, Taheri M, Mei Z, Lim I, Khalil MA, Carter-Cooper B, Fanaroff RE, Ong CS, Schneider EB, Chang S, et al. Lung adenocarcinoma-derived IFN-gamma promotes growth by modulating CD8\u2009+\u2009T cell production of CCR5 chemokines. J Clin Invest. 2025;135(17):e191070.","DOI":"10.1172\/JCI191070"},{"key":"2688_CR165","doi-asserted-by":"crossref","unstructured":"Maitz K, Valadez-Cosmes P, Raftopoulou S, Kindler O, Kienzl M, Bolouri H, Houghton AM, Schicho R, Heinemann A, Kargl J. Altered treg infiltration after Discoidin Domain Receptor 1 (DDR1) inhibition and knockout promotes tumor growth in lung adenocarcinoma. Cancers (Basel). 2023;15(24):5767.","DOI":"10.3390\/cancers15245767"},{"key":"2688_CR166","doi-asserted-by":"crossref","unstructured":"Mittal P, Wang L, Akimova T, Leach CA, Clemente JC, Sender MR, Chen Y, Turunen BJ, Hancock WW. The CCR2\/MCP-1 chemokine pathway and lung adenocarcinoma. Cancers (Basel). 2020;12(12):3723.","DOI":"10.3390\/cancers12123723"},{"key":"2688_CR167","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4049\/jimmunol.2300154","volume":"213","author":"N Diamantopoulos","year":"2024","unstructured":"Diamantopoulos N, Li J, Bouchard A, Joumier L, Mohammaei S, Panneton V, Chang J, Malleshaiah M, Suh WK. ICOS-expressing Regulatory T Cells Influence the Composition of Antitumor CTL Populations. J Immunol. 2024;213:753\u201362.","journal-title":"J Immunol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02688-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02688-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02688-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:03:38Z","timestamp":1785798218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02688-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":167,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2688"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02688-5","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"187"}}